{"brief_title": "A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients", "brief_summary": "The purpose of this study is to see whether it is better to take delavirdine (DLV) plus indinavir (IDV) plus zidovudine (ZDV) twice a day or three times a day.", "detailed_description": "Patients are divided into 2 treatment groups; the groups are balanced with respect to viral load. Group A receives ZDV, DLV, and IDV 3 times daily. Group B receives ZDV, DLV, and IDV 2 times daily. Patients are evaluated for changes from baseline in viral load and CD4 cell count.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Zidovudine", "criteria": "Inclusion Criteria You may be eligible for this study if you: - Are HIV-positive. - Have a viral load (level of HIV in the blood) of at least 20,000 copies/ml. - Have a CD4 cell count of at least 50 cells/mm3. - Are at least 14 years old (consent of parent or guardian is required if under 18). Exclusion Criteria You will not be eligible for this study if you: - Have ever taken an anti-HIV drug other than ZDV. - Have taken ZDV for more than 1 month.", "gender": "All", "minimum_age": "14 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002236.xml"}